No Data
No Data
Shanghai Longyao, a subsidiary of China Biotechnology Service (08037), was recognized as a specialized, special and new small and medium-sized enterprise in Shanghai in 2024
China Biotechnology Service (08037) announced that Shanghai Longyao Biotechnology Co., Ltd., an indirect non-wholly-owned subsidiary of the company...
China Biotech Services (08037.HK) placement of convertible bonds lapses
Gelonghui, April 30, 丨 China Biotechnology Service (08037.HK) announced that due to recent market conditions, placement agents have not successfully placed convertible bonds as of April 30, 2024 (the final deadline). As a result, the placement agreement did not become unconditional and expired on April 30, 2024. According to the placement agreement, all obligations and liabilities of the placement agent and the company under this agreement shall cease and end, and the parties to this agreement shall not file any claim against the other party other except for any prior breach of contract.
China Biotech Service and Hong Kong-Shenzhen Innovation and Technology Park Corporation signed a memorandum of understanding
China Biotechnology Service (08037) announced that the Hong Kong-Shenzhen Innovation and Technology Park Limited signed a memorandum of understanding with about 60 partner organizations (including the company), and held the Hong Kong-Shenzhen Innovation and Technology Park partner launch ceremony on April 18, 2024. According to the memorandum of understanding between the company and the Hong Kong-Shenzhen Innovation and Technology Park Corporation, the parties concerned have agreed to cooperate in the development of the Hong Kong-Shenzhen Innovation and Technology Park located in the Lok Ma Chau Hetao area of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone.
It is expected to open the first BNCT boron neutron treatment center in Hong Kong, and the Chinese Medicine Service (08037) wants to enter the Hong Kong-Shenzhen Science and Technology Innovation Park
The reason behind the memorandum of understanding with the Hong Kong-Shenzhen Science and Technology Innovation Park is a concrete reflection of China's biotechnology services speeding up the commercialization process of boron neutron capture therapy.
China Biotechnology Services (08037.HK) signs MOU with Hong Kong-Shenzhen Innovation and Technology Park
Gelonghui, April 18, 丨 China Biotechnology Service (08037.HK) announced that the Hong Kong-Shenzhen Innovation and Technology Park Limited (“Hong Kong-Shenzhen Innovation and Technology Park Corporation”) signed a memorandum of understanding with about 60 partner organizations (including companies), and held the Hong Kong-Shenzhen Innovation and Technology Park partner launch ceremony on April 18, 2024. According to the Memorandum of Understanding between the Company and Hong Kong-Shenzhen Innovation and Technology Park Corporation (collectively referred to as the “parties concerned”), the parties concerned have agreed (among others) to cooperate in the development of the Hong Kong-Shenzhen Innovation and Technology Park in the Lok Ma Chau Hetao area of the Hetao Shenzhen-Hong Kong Science and Technology Cooperation Zone. Development of boron neutron capture in cancer treatment
中國生物科技服務:2023 年報
No Data